NEW YORK (GenomeWeb) – Vermillion reported after the close of the market on Thursday an 89 percent jump in its first quarter revenues
For the three months ended Sept, 30, the Austin, Texas-based cancer diagnostics firm said that total revenues rose to $623,000 from $330,000 in the year-ago quarter.
Product revenues were $581,000, up from $330,000 in Q3 2015. Service revenues from the company's Aspira IVD business was $42,000. Vermillion had no service revenues in Q3 2015 as Aspira IVD was not yet operating.